Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pomalidomide Celgene

- PMLiVE

FDA briefing document backs J&J’s one-dose COVID-19 vaccine

Company is seeking an emergency use authorisation in the US

- PMLiVE

J&J submits one-dose COVID-19 vaccine to WHO for emergency use listing

In phase 3, J&J's vaccine was 66% effective overall at preventing moderate-to-severe COVID-19

- PMLiVE

J&J completes enrolment for late-stage COVID-19 vaccine trial

Company announces that around 45,000 participants have been enrolled

- PMLiVE

J&J trims the size of its phase 3 COVID-19 vaccine trial

Company cuts size of participant population from 60,000 to 40,000

- PMLiVE

EMA launches rolling review of J&J’s COVID-19 vaccine

Vaccine entered phase 3 testing in September

- PMLiVE

FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions

Inspection of third-party manufacturing plant delayed due to COVID-19

- PMLiVE

Both AZ and J&J set to resume US COVID-19 vaccine trials

Both companies paused their trials after separate participant illness events

Visual Storytelling in HealthTech

Rodney Hu, founder of 209|Digital and a popular podcast host. We explore Rodney’s work within the HealthTech space and what he believes has to happen for the healthcare industry to more...

Impetus Digital

- PMLiVE

J&J halts COVID-19 vaccine study after unexplained participant illness

Company convened data and safety monitoring board to review event

- PMLiVE

Phase 1/2a results for J&J’s COVID-19 vaccine show early promise

Vaccine produced neutralising antibodies in 98% of participants

- PMLiVE

J&J advances COVID-19 vaccine into phase 3 testing

News comes after last week's announcement from Novavax on its launch of a UK-based phase 3 trial

- PMLiVE

FDA hands BMS and bluebird bio a priority review for ide-cel

Updated review accepted after refuse-to-file letter was issued in May

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links